All In Biotech

Drug Trial Radar · NCT07243379

A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia

Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

495

Planned (sponsor's estimate)

Start

Sep 25, 2025

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
Henan Cancer Hospital
First posted
Nov 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.

Conditions

  • Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia
  • Multicenter Observational Study

Interventions

  • Nanocrystalline Megestrol AcetateDrug

    Nanocrystalline Megestrol Acetate oral suspension, with a specification of 125 mg/mL, administered orally at a dose of 5 mL per day (625 mg/day), and the primary endpoint efficacy collection will be conducted in the 4th week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with improved appetite at Week 4 based on the A/CS-12 scale.Time frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital, Affiliated to Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.